Free cash flow generation remains highly erratic, evidenced by a swing from a negative $11.6 million in 2025Q4 to a positive $7.3 million in 2026Q1, largely driven by lumpy capital expenditures of $15.1 million.
| Cash from Operations | 15.84M | 10.52M | 969K | 6.82M | 4.82M | -4.72M | -22.35M | -18.03M | -8.14M | -4.72M |
| Operating CF Margin % | - | 13.16% | 2.48% | 21.54% | 22.69% | -21.62% | -57297.44% | -1879.67% | - | - |
| Operating CF Growth % | -314.06% | 986.07% | -85.78% | 41.36% | 202.12% | 78.87% | -23.97% | -121.31% | -72.64% | - |
| Net Income | -1.48M | -4.6M | -3.82M | -936K | -9.02M | -1.96M | -27.97M | -18.32M | -12.74M | -7.16M |
| Depreciation & Amortization | 4.16M | 4.04M | 1.15M | 901K | 1.77M | 462K | 651K | 447K | 63K | 13K |
| Stock-Based Compensation | 4.31M | 5.51M | 3.17M | 3.14M | 4.22M | 3.38M | 2.58M | 1.89M | 1.85M | 2.64M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | -546K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 7.2M | 6.43M | 1.18M | 184K | 189K | 148K | 1.39M | 16K | 2.58M | 1.29M |
| Working Capital Changes | 1.64M | -859K | -698K | 3.53M | 7.66M | -6.21M | 1.01M | -2.06M | 99K | 623K |
| Change in Receivables | 2.99M | -6.4M | -3.12M | -1.56M | 3.62M | -5.42M | 425K | -473K | 0 | 0 |
| Change in Inventory | -4.94M | -5.88M | -1.31M | -354K | -7K | 692K | -862K | -380K | 0 | 0 |
| Change in Payables | 8.61M | 6.81M | 2.32M | 53K | -8K | -570K | 1.77M | -377K | 413K | 539K |
| Cash from Investing | -15.41M | -333K | -40.01M | -775K | -2.79M | -2.56M | -50K | -1.85M | -236K | -130K |
| Capital Expenditures | -15.41M | -333K | -26K | -775K | -38K | -3.26M | -50K | -1.1M | -236K | -130K |
| CapEx % of Revenue | 17.72% | 0.42% | 0.07% | 2.45% | 0.18% | 14.93% | 128.21% | 114.29% | - | - |
| Acquisitions | 0 | 0 | -30M | 0 | 0 | 700K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -9.99M | 0 | -2.75M | 0 | 0 | -750K | 0 | 0 |
| Cash from Financing | 1.81M | 815K | 32.59M | -957K | -134K | 391K | 31.63M | 5.2M | 21.96M | 18M |
| Debt Issued (Net) | 0 | 0 | 24.15M | -1.16M | -385K | -150K | 2.48M | 4.75M | 0 | 0 |
| Equity Issued (Net) | 1.81M | 598K | 8.19M | 0 | 0 | 541K | 28.78M | 0 | 22.8M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.05M | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 217K | 248K | 198K | 251K | 0 | 367K | 453K | 205K | 18M |
| Net Change in Cash | 2.24M | 11.01M | -6.45M | 5.08M | 1.9M | -6.89M | 9.23M | -14.67M | 13.58M | 13.16M |
| Free Cash Flow | 15.43M | 10.19M | 943K | 6.04M | 2.03M | -7.98M | -22.4M | -19.87M | -8.38M | -4.85M |
| FCF Margin % | 17.75% | 12.75% | 2.42% | 19.09% | 9.57% | -36.55% | -57425.64% | -2072.16% | - | - |
| FCF Growth % | 179.55% | 980.7% | -84.39% | 197.1% | 125.48% | 64.37% | -12.7% | -137.11% | -72.88% | - |
| FCF per Share | 0.49 | 0.38 | 0.04 | 0.24 | 0.08 | -0.32 | -1.07 | -1.12 | -1.31 | -0.28 |
| FCF Conversion (FCF/Net Income) | -10.46x | -2.29x | -0.25x | -7.28x | -0.53x | 2.41x | 0.80x | 0.98x | 0.64x | 0.66x |
| Interest Paid | 2.68M | 0 | 665K | 842K | 730K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 110K | 0 | 82K | 247K | 0 | 0 | 0 | 0 | 0 | 0 |
Orphan drug regulatory dependency
As reported in recent financial statements, Eton's operating cash flow frequently decouples from net income, with the OCF/NI ratio reaching a volatile 4.77 in 2026Q1, suggesting that non-cash items and working capital swings significantly distort the company's reported profitability metrics on a quarterly basis.
The wide variance between net income and operating cash flow indicates that reported earnings are not yet a reliable proxy for the company's underlying cash-generating capacity. Investors should monitor whether this divergence persists as the company scales, as it may imply that accounting accruals are masking the true cash costs of commercializing its orphan drug portfolio.
Based on historical cash flow data, Eton's free cash flow trajectory remains highly erratic, swinging from a negative $11.6 million in 2025Q4 to a positive $7.3 million in 2026Q1, which highlights the inherent instability in the company's current transition toward a self-sustaining commercial model.
The lack of a consistent FCF trend suggests that the company is still in a high-investment phase where cash flow is heavily influenced by the timing of product launches and associated working capital requirements. This volatility warrants caution, as it indicates that the business has not yet achieved the predictable cash conversion necessary to fund its pipeline internally.
According to recent SEC filings, Eton's capital intensity is characterized by sporadic, large-scale outflows, such as the $15.1 million expenditure in 2026Q1, which represents a significant departure from the minimal maintenance spending observed in prior periods and suggests aggressive investment in long-term infrastructure or product development.
The high CapEx/Revenue ratio of 62.1% in 2026Q1 indicates that the company is prioritizing growth-oriented capital allocation over immediate cash preservation. Analysts should investigate whether these expenditures are recurring in nature or represent one-time investments in manufacturing capabilities that could eventually lead to improved operating leverage.
As evidenced by the cash flow statements, working capital changes have been a major source of volatility, including a $17.4 million outflow in 2025Q4 followed by a $2.5 million inflow in 2026Q1, suggesting that inventory and receivable management remains a primary driver of short-term liquidity fluctuations.
These sharp swings in working capital suggest that the company's cash position is highly sensitive to the timing of inventory stocking and the collection cycles of its hospital and orphan drug customers. Such fluctuations may indicate that the company lacks a fully optimized supply chain, potentially creating periodic liquidity pressure that requires careful management.
Financial disclosures indicate that stock-based compensation remains a consistent non-cash expense, with $1.1 million recorded in 2025Q4, which suggests that the company's reported cash flow from operations may be artificially bolstered by these non-cash adjustments that do not reflect the true economic cost of talent retention.
The reliance on stock-based compensation to manage cash outflows warrants further investigation, as it may be masking the true cost of operating the business. Investors should adjust cash flow metrics to account for these recurring non-cash charges to better understand the company's actual ability to fund operations without shareholder dilution.
Quick answers to the most common questions about buying ETON stock.
Eton Pharmaceuticals, Inc. (ETON) generated $10.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Eton Pharmaceuticals, Inc. (ETON) generated $10.2M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Eton Pharmaceuticals, Inc. (ETON) spent $0.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.